目前关于肠衰竭相关肝病（IFALD）的认识：一篇叙述性综述。
Current Insights Regarding Intestinal Failure-Associated Liver Disease (IFALD): A Narrative Review.
机构信息
Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Association of General Practice/Family Medicine of South-East Europe (AGP/FM SEE), St. Vladimir Komarov No. 40/6, 1000 Skopje, North Macedonia.
出版信息
Nutrients. 2023 Jul 17;15(14):3169. doi: 10.3390/nu15143169.
Abstract
Intestinal failure-associated liver disease (IFALD) is a spectrum of liver disease including cholestasis, biliary cirrhosis, steatohepatitis, and gallbladder disease in patients with intestinal failure (IF). The prevalence of IFALD varies considerably, with ranges of 40-60% in the pediatric population, up to 85% in neonates, and between 15-40% in the adult population. IFALD has a complex and multifactorial etiology; the risk factors can be parenteral nutrition-related or patient-related. Because of this, the approach to managing IFALD is multidisciplinary and tailored to each patient based on the etiology. This review summarizes the current knowledge on the etiology and pathophysiology of IFALD and examines the latest evidence regarding preventative measures, diagnostic approaches, and treatment strategies for IFALD and its associated complications.
摘要
肠衰竭相关肝病（IFALD）是一组肝脏疾病，包括肠衰竭（IF）患者的胆汁淤积、胆汁性肝硬化、肝炎和胆囊疾病。IFALD 的患病率差异很大，儿科患者的范围为 40-60%，新生儿高达 85%，成人患者为 15-40%。IFALD 的病因复杂且多因素；危险因素可能与肠外营养相关或与患者相关。因此，IFALD 的治疗方法是多学科的，并根据病因针对每个患者进行定制。本综述总结了 IFALD 的病因和病理生理学的现有知识，并研究了关于 IFALD 及其相关并发症的预防措施、诊断方法和治疗策略的最新证据。
相似文献
1
Current Insights Regarding Intestinal Failure-Associated Liver Disease (IFALD): A Narrative Review.目前关于肠衰竭相关肝病（IFALD）的认识：一篇叙述性综述。
Nutrients. 2023 Jul 17;15(14):3169. doi: 10.3390/nu15143169.
2
New insights into intestinal failure-associated liver disease in adults: A comprehensive review of the literature.成人肠衰竭相关肝病的新见解：文献综述。
Saudi J Gastroenterol. 2021 Jan-Feb;27(1):3-12. doi: 10.4103/sjg.sjg_551_20.
3
Intestinal failure-associated liver disease in the neonatal ICU: what we know and where we're going.新生儿重症监护病房中的肠衰竭相关肝病：我们所了解的情况及未来方向。
Curr Opin Pediatr. 2022 Apr 1;34(2):184-190. doi: 10.1097/MOP.0000000000001105.
4
The gut microbiome and intestinal failure-associated liver disease.肠道微生物群与肠衰竭相关肝病。
Hepatobiliary Pancreat Dis Int. 2023 Oct;22(5):452-457. doi: 10.1016/j.hbpd.2023.07.002. Epub 2023 Jul 9.
5
Exploring the long-term risk factors associated with intestinal failure-associated liver disease in pediatric and adult patients: The role of lipid injectable emulsions in the development of liver disease.探讨与儿童和成人患者肠衰竭相关肝病相关的长期风险因素：脂质注射用乳剂在肝病发展中的作用。
Nutr Clin Pract. 2022 Oct;37(5):1142-1151. doi: 10.1002/ncp.10824. Epub 2022 Feb 11.
6
Clinical approach to the management of Intestinal Failure Associated Liver Disease (IFALD) in adults: A position paper from the Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN.成人肠衰竭相关肝病（IFALD）管理的临床方法：ESPEN 家庭人工营养和慢性肠衰竭特别兴趣小组的立场文件。
Clin Nutr. 2018 Dec;37(6 Pt A):1794-1797. doi: 10.1016/j.clnu.2018.07.006. Epub 2018 Jul 9.
7
New Insights Into Intestinal Failure-Associated Liver Disease in Children.儿童相关性肠衰竭肝病的新见解。
Hepatology. 2020 Apr;71(4):1486-1498. doi: 10.1002/hep.31152. Epub 2020 Mar 18.
8
Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure.预测、识别和评估儿童肠衰竭相关肝组织病理学疾病活动度的研究。
J Hepatol. 2021 Mar;74(3):593-602. doi: 10.1016/j.jhep.2020.09.023. Epub 2020 Sep 28.
9
Intestinal failure-associated liver disease: management and treatment strategies past, present, and future.肠衰竭相关肝病：过去、现在及未来的管理与治疗策略
Semin Liver Dis. 2007 Aug;27(3):251-8. doi: 10.1055/s-2007-985070.
10
Intestinal failure-associated liver disease (IFALD): insights into pathogenesis and advances in management.肠衰竭相关肝病（IFALD）：发病机制的深入了解和治疗进展。
Hepatol Int. 2020 May;14(3):305-316. doi: 10.1007/s12072-020-10048-8. Epub 2020 Apr 30.
引用本文的文献
1
100% Fish oil-based lipid emulsion inhibits hepatic stellate cell activation via suppression of the TGF-β1 autocrine signaling.100%基于鱼油的脂质乳剂通过抑制转化生长因子-β1自分泌信号传导来抑制肝星状细胞活化。
Hum Cell. 2025 Aug 27;38(5):153. doi: 10.1007/s13577-025-01283-y.
2
Enteral Nutrition in Neonatal Cholestasis: An Up-to-Date Overview.新生儿胆汁淤积症中的肠内营养：最新综述
Nutrients. 2025 May 26;17(11):1794. doi: 10.3390/nu17111794.
3
Harnessing algae oil as a sustainable DHA source for parenteral nutrition in vegan patients.利用藻油作为素食患者肠外营养的可持续DHA来源。
Sci Rep. 2025 May 27;15(1):18548. doi: 10.1038/s41598-025-03319-7.
4
Curcumin: A Natural Warrior Against Inflammatory Liver Diseases.姜黄素：对抗炎症性肝病的天然斗士。
Nutrients. 2025 Apr 18;17(8):1373. doi: 10.3390/nu17081373.
5
Pathogenesis and Management of Intestinal Failure-Associated Liver Disease.肠衰竭相关肝病的发病机制与管理
Semin Liver Dis. 2025 Mar;45(1):66-80. doi: 10.1055/a-2545-7370. Epub 2025 Feb 27.
6
Acquired Zinc Deficiency in Preterm Infant Post-Surgery for Necrotizing Enterocolitis (NEC) on Prolonged Total Parenteral Nutrition (TPN).坏死性小肠结肠炎（NEC）术后接受长期全肠外营养（TPN）的早产儿获得性锌缺乏症。
Pediatr Rep. 2024 Jun 26;16(3):551-557. doi: 10.3390/pediatric16030046.
7
Investigation of parenteral nutrition-induced hepatotoxicity using human liver spheroid co-cultures.使用人源肝球体共培养物研究肠外营养相关性肝毒性。
Arch Toxicol. 2024 Sep;98(9):3109-3126. doi: 10.1007/s00204-024-03773-8. Epub 2024 May 14.
本文引用的文献
1
Untargeted Metabolomics Reveal Parenteral Nutrition-Associated Alterations in Pediatric Patients with Short Bowel Syndrome.非靶向代谢组学揭示短肠综合征患儿肠外营养相关的改变
Metabolites. 2022 Jun 27;12(7):600. doi: 10.3390/metabo12070600.
2
Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases.色氨酸代谢、肠道微生物群与免疫系统之间的相互作用作为非酒精性脂肪性肝病（NAFLD）和代谢性疾病的潜在驱动因素
Metabolites. 2022 Jun 2;12(6):514. doi: 10.3390/metabo12060514.
3
Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP).特杜古肽治疗儿科肠衰竭：意大利儿科胃肠病学、肝病学和营养学学会（SIGENP）立场声明。
Dig Liver Dis. 2022 Oct;54(10):1320-1327. doi: 10.1016/j.dld.2022.04.028. Epub 2022 May 31.
4
Intravenous Lipid Emulsions in the Prevention and Treatment of Liver Disease in Intestinal Failure.静脉内脂肪乳剂在预防和治疗肠衰竭相关肝病中的应用。
Nutrients. 2021 Mar 10;13(3):895. doi: 10.3390/nu13030895.
5
New insights into intestinal failure-associated liver disease in adults: A comprehensive review of the literature.成人肠衰竭相关肝病的新见解：文献综述。
Saudi J Gastroenterol. 2021 Jan-Feb;27(1):3-12. doi: 10.4103/sjg.sjg_551_20.
6
Impact of Parenteral Lipid Emulsion Components on Cholestatic Liver Disease in Neonates.肠外脂肪乳剂成分对新生儿胆汁淤积性肝病的影响。
Nutrients. 2021 Feb 4;13(2):508. doi: 10.3390/nu13020508.
7
Current strategies for managing intestinal failure-associated liver disease.目前管理肠衰竭相关肝病的策略。
Expert Opin Drug Saf. 2021 Mar;20(3):307-320. doi: 10.1080/14740338.2021.1867099. Epub 2020 Dec 30.
8
Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure.预测、识别和评估儿童肠衰竭相关肝组织病理学疾病活动度的研究。
J Hepatol. 2021 Mar;74(3):593-602. doi: 10.1016/j.jhep.2020.09.023. Epub 2020 Sep 28.
9
Intestinal Failure-Associated Liver Disease in Neonates.新生儿相关性肝肠衰竭
Neoreviews. 2020 Sep;21(9):e591-e599. doi: 10.1542/neo.21-9-e591.
10
Composite Lipid Emulsion for the Infant at Risk of Intestinal Failure-associated Liver Disease: The Canadian Perspective.肠衰竭相关肝病风险婴儿的复合脂肪乳剂：加拿大的观点。
J Pediatr Gastroenterol Nutr. 2020 Sep;71(3):283-287. doi: 10.1097/MPG.0000000000002794.
Zotero 插件